Skip to main content

Knowledge Zone

Brief summaries of the market access landscape for medical technologies and in-vitro diagnostic tests in European countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Decree relating to the RIHN framework reform published in France

On March 31, 2024, the Ministry of Labor, Health, and Solidarity published a Decree in the Official Journal of the French Republic relating to the conditions of coverage of innovative tests within the RIHN framework. The Decree defined eligibility criteria for the framework, provided details about collecting clinical and economic data, conditions for coverage, and the possibility for direct applications by the manufacturer, but also introduced a limitation on the duration of coverage to six years. As per earlier provisions of RIHN reform announced at the end of 2022, the French National Authority for Health now has a clearly defined role in the process and should evaluate an innovative test for inclusion into the NABM Nomenclature before the coverage period expires (i.e., the transition of a test from RIHN to NABM Nomenclature).

The Decree came into force the day after its publication.

More details can be found in French here

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.